Apollomics Regains Compliance With Nasdaq's Minimum Bid Price Requirement
Apollomics Regains Compliance With Nasdaq's Minimum Bid Price Requirement
Apollomics Inc. (NASDAQ:APLM) (the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on December 10, 2024, it received a notification (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Rule 5550(a)(2) (the "Bid Price Requirement"), and Nasdaq has determined to continue the listing of the Company's Class A ordinary shares ("Class A Ordinary Shares") on the Nasdaq Capital Market under the symbol "APLM."
開發治療難以治療的癌症藥物的臨牀階段生物製藥公司Apollomics Inc.（納斯達克股票代碼：APLM）（「公司」）今天宣佈，2024年12月10日，它收到了納斯達克股票市場有限責任公司（「納斯達克」）的通知（「通知」），稱該公司已恢復遵守維持最低收盤價爲每股1.00美元的要求，根據納斯達克規則5550 (a) (2)（「投標價格要求」）的規定，納斯達克已決定繼續該公司A類普通股的上市（「A類普通股」）在納斯達克資本市場上市，股票代碼爲 「apLM」。
